MedTrace Logo

Collection of Tissue Samples for Study of Multidrug Resistance

NCT00880503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 325

Last updated 2019-12-16

No results posted yet for this study

Summary

Background:

Resistance to cancer chemotherapy develops in patients, rendering certain treatments ineffective. Despite much research, the prevailing cause of drug resistance is not known.

One mechanism for drug resistance involves a protein called P-glycoprotein, or Pgp, which reduces the effectiveness of cancer treatments by "pumping" anti-cancer drugs out of tumor cells where they are supposed to work against the disease.

Objectives:

To identify and evaluate more thoroughly the roles of Pgp and other substances in mediating drug resistance.

Eligibility:

Patients enrolled in clinical trials of cancer therapies at the Children's Hospital of Pittsburgh; Cancer Centers of Carolinas; Arizona Clinical Research Center; University of Copenhagen; and Herlev Hospital, Copenhagen who have consented to the use of blood, tissue, or tumor samples for laboratory studies.

Design:

Blood, tumor, and tissue samples are collected from participants and sent to the NCI for various laboratory analyses.

...

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • William D Figg, Pharm.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-19
Completion
2018-02-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880503 on ClinicalTrials.gov